Year: 2018
Type: article
Abstract: Polo-like kinase 1 (Plk1) is overexpressed in a wide spectrum of human tumors, being frequently considered as an oncogene and an attractive cancer target. However, its contribution to tumor development is unclear. Using a new inducible knock-in mouse model we report here that Plk1 overexpression results in abnormal chromosome segregation and cytokinesis, generating polyploid cells with reduced proliferative potential. Mechanistically, these cytokinesis defects correlate with defective loading of Cep55 and ESCRT complexes to the abscission bridge, in a Plk1 kinase-dependent manner. In vivo, Plk1 overexpression prevents the development of Kras-induced and Her2-induced mammary gland tumors, in the presence of increased rates of chromosome instability. In patients, Plk1 overexpression correlates with improved survival in specific breast cancer subtypes. Therefore, despite the therapeutic benefits of inhibiting Plk1 due to its essential role in tumor cell cycles, Plk1 overexpression has tumor-suppressive properties by perturbing mitotic progression and cytokinesis.
Source: Nature Communications
Language: English
Subfield: Cell Biology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $6,990
Funders: Howard Hughes Medical Institute, Deutsches Krebsforschungszentrum, Worldwide Cancer Research, Comunidad de Madrid, Cancer Research UK, European Commission, Rosetrees Trust, Consejería de Sanidad, Comunidad de Madrid, European Research Council, Seventh Framework Programme, European Regional Development Fund, National Human Genome Research Institute, National Cancer Institute, FP7 Ideas: European Research Council
Awards: G1439616544, G2228978438, MARie CuRIe AGEing Network, G265847165, G2832993492, G2955275115, G3207356259, Defining the Impact of Chromosome Instability in Tumor Initiation, Maintenance and Relapse, G393177772, G4073353359, G4820032654, G496129201, G5702163051, G7468827021, G7748227364, Dissecting the Role of Chromosome Instability in Cancer, G871084439
OpenAlex ID: W2883461704
